Parecoxib Pharmacia Corp

IDrugs

Volumn 4, Issue 8, 2001, Pages 939-944

  Gotta, Alexander W ^a  

^a SUNY DOWNSTATE MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 0008957628     PISSN: 13697056     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (61)

1. Structral basis for selective Inhibition of cyclooxygenase-2 by antiinflammatory agents. Kurumbail RG, Stevens AM, Gierse JK, McDonald JJ, Stegeman RA, Pak JY, Gildehaus D, Miyashiro JM, Penning TD, Seibert K, Isakson PC, Stallings WC NATURE 1996 384 6610 644 - 648 • A clear description of the structural features in COX-2 that can be used to design more selective inhibitors.
2. Monsanto Company ANNUAL REPORT 1996 December 31
3. 289S06 AHP and Pfizer will be partners In Célébra after Monsanto merger. FDC REPORTS PINK SHEET 1998 60 23 8
4. Monsanto reports 1998 fourth-quarter and full-year results. Monsanto Co PRESS RELEASE 1999 January 21
5. Monsanto/American Home Products product pipeline. Monsanto Co COMPANY WORLD WIDE WEB SITE 1998 June 01
6. A robust product pipeline (from 1997 Annual Report). Monsanto Co COMPANY WORLD WIDE WEB SITE 1999 February 08
7. COX-2 Inhibitors - IBC Conference, Coronado, ÇA, USA. IDDB MEETING REPORT 1993 April 12-13 .
8. Characterization of rofecoxib as a cyclooxygenase-2 isoform inhibitor and demonstration of analgesia in the dental pain model. Enrich EW, Dallob A, De Lepeleire I, Van Hecken A, Riendeau D, Yuan W, Porras A, Wittreich J, Seibold JR, De Schepper P, Mehlisch DR, Gertz BJ CLIN PHARMACOL THER1999 65 3 336 - 347 • The analgesic effect of NSAIDs derives primarily from inhibition of COX-2.
9. International Association for the Study of Pain - Ninth World Congress (Part II), Vienna, Austria. Dickenson AH, Carpenter K, Suzuki R IDDB MEETING REPORT!999 August 22-27
10. Searle. FORMULARY 1999 34 10 Suppl 91 - 93
11. International Association for the Study of Pain (Part IV), Vienna, Austria. IDDB MEETING REPORT 1999 August 23-27
12. Searle oncology given boost by pending P&U merger, antibody deal. FDC REPORTS PINK SHEET2000 62 3 21 - 22
13. SG Cowen ANALYST REPORT1999 December 20
14. Global Healthcare Bulletin. Merrill Lynch ANALYST REPORT 2000 March 16
15. 2000672PI-8 • Intravenous parecoxib is as effective as intravenous ketorolac in the treatment of dental pain.
16. Correlation of pharmacokinetics (PK) with onset and duration of analgesia of intramuscular doses of parecoxib, in postoperative dental pain. Mehlisch D, Kuss M, Bauman A, Baum D, Karim A, Hubbard R CLIN PHARMACOL THER 2000 67 2 PIII-7 • Intramuscular parecoxib is as effective as intramuscular ketorolac against dental pain.
17. Pharma pipelines. Lehman Brothers ANALYST REPORT2000 April 05
18. An endocopic study of the gastroduodenal effects of SC-69142A, a parenteral COX-2-specific inhibitor in the elderly Hubbard RC, Kuss ME, LeComte DL, Pan X, Talwalker S, Geis GS GASTROENTEROLOGY 2000 118 4 Suppl 2 AbS 1455
19. Gastrointestinal effects of Searle's Parecoxib sodium similar to placebo study: COX-2 specific Inhibitor safer than intravenous NSAID in elderly. GD Searle & Co PRESS RELEASE200Q May 24
20. A-4TJ5-Methyl-3-phenylisoxazol-4-yl)-phenyl]sulfonyl] propanamide, sodium salt, parecoxib sodium: a potent and selective inhibitor of COX-2 for parenteral administration. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Zhang YY, Seibert K J MED CHEM2000 43 9 1661 - 1663 • The first two selective COX-2 inhibitors, celecoxib (GD Searle & Co) and rofecoxib (Merck & Co), were launched in 1999. Although both drugs have good selectivity for COX-2 relative to COX-1, their properties are considered suboptimal for certain uses. Searle (Pharmacia) is addressing this by developing valdecoxib and parecoxib. The latter is a selective COX-2 inhibitor with good aqueous solubility, in contrast to other agents designed to provide potent non-narcotic analgesic effects without the side effects of ketorolac.
21. Pharmacia Corp. Arnold & J Bleichroeder ANALYST REPORT 2000 March 22
22. Pharmacia Corp. Morgan Stanley Dean Witter ANALYST REPORT 2000 April 04
23. Product Pipeline - 1998 annual report - investor relations Monsanto. Monsanto Co COMPANY WORLD WIDE WEB SITE 2000 June 11
24. Summary of Digestive Disease Week 2000, San Diego, CA, USA. Hilton J IDDB MEETING REPORT2000 May 21-24
25. Monsanto Co ANNUAL REPORT 1999 December 31
26. Drug development pipeline. Pharmacia Corp COMPANY COMMUNICATION 2000 July 13
27. Pharmacia Corp - Initiating coverage with an outperform rating. Morgan Stanley Dean Witter ANALYST REPORT 2000 April 04 1 - 12
28. Preview of the XVIth International Symposium on Medicinal Chemistry, Bologna, Italy, Eyles A IDDB MEETING REPORT 2000 September 18-22
29. Global healthcare bulletin. Merrill Lynch ANALYST REPORT 2000 September 01
30. Post-operative pain management failed to improve over the past decade - phase I studies of investigational injectable COX-2 inhibitor reported. Pharmacia Corp PRESS RELEASE 2000 October 18 • Pain therapy is still inadequate and too many patients suffer significant postoperative pain. The use ofketorolac is limited.
31. Pharmacia's injectable COX-2 specific inhibitor's safety and compatibility well tolerated, compatible with other drugs studied. Pharmacia Corp PRESS RELEASE20QO October 18
32. Pharmacia reports 57% increase in third quarter earnings per share. Pharmacia Corp PRESS RELEASE2000 October 30
33. American Society of Anesthesiologists 51st Annual Meeting (Part II), San Francisco, CA, USA. Gotta AW IDDB MEETING REPORT 2000 October 14-18
34. Pharmacia submits New Drug Application for injectable parecoxib sodium - first parenteral COX-2-specific agent for management of acute pain associated with surgery or trauma. Pharmacia Corp PRESS RELEASE 2000 October 30
35. New injectable COX-2 specific inhibitor superior to morphine, comparable to ketorolac - study shows effective, safe, non-narcotic control of post-operative pain. Pharmacia Corp PRESS RELEASE 2000 November 06
36. Pharmacia's COX-2 inhibitor well-tolerated, compatible with other drugs. PHARMA JPN2000 1720 18
37. Pharmacia to launch parecoxib with Zyvox sales force: no partner needed. FDC REPORTS PINK SHEET2000 62 45 6 - 7
38. Monitor: Molecules and profiles. Lloyd AW DRUG DISC TODAY 2000 5 8 373 - 375
39. [Perspective for safer alternatives. COX-2-selective NSAID'sJ. COX-2-selective NSAID's: Opties voor velliger alternatieven. Van
40. Roon EN, Brouwers JRBJ, Posthuma RM PHARM WEEKBL 2000 135 5 162- 167
41. Yamanouchi Pharmaceutical Co Ltd ANNUAL REPORT 2000 December 4
42. An endoscopie study of the gastroduodenal effects of SC69124A, a parenteral COX-2-specific inhibitor, in the elderly. Hubbard RC, Kuss ME, LeComte DL, Pan X, Talwalker S, Geis GS GASTROENTEROLOGY2000118 4 Suppl 2 Pt 1 A250 • Parecoxib is less toxic than ketorolac.
43. Discovery and development of COX-2 specific inhibitors. Seibert K PROSTAGLANDINS OTHER LIPID MEDIATORS 1999 59 1 -6 157
44. New York State Society of Anesthesiologists 54th Postgraduate Assembly, New York, NY, USA. Gotta AW IDDB MEETING REPORT 2000 December 9-13
45. Pharmacia could see double COX-2 NME drug approvals in 2001. FDC REPORTS PINKSHEET2001 63 212 -14
46. Pharmacia reports 33% increase in fourth-quarter earnings per share. Pharmacia Corp PRESS RELEASE2W\ February 12
47. Study data show single dose of investigational injectable COX-2 specific inhibitor offered superior analgesia to single dose of morphine in relief of post-surgical pain - parecoxib sodium iv provided welltolerated, non-narcotic control of pain in total knee replacement study. Pharmacia Corp PRESS RELEASE200I March 02
48. Highlights of Pharmacia's successful first year presented at annual shareholder meeting. Pharmacia Corp PRESS RELEASE200'\ April 17
49. Study data show that investigational injectable COX-2 specific inhibitor reduced the need for narcotics in treatment of pain following surgery: parecoxib sodium IV reduced morphine consumption, improved pain relief in study of total hip replacement. Pharmacia Corp PRESS RELEASE2001 April 23 • Parecoxib decreases morphine requirement after total hip or total knee replacement.
50. Evaluation of intravenous parecoxib for the relief of acute postsurgical pain. Jain KK EXP OPIN INVEST DRUGS 2000 9 11 2717 - 2723
51. W-[[(5-fnethyl-3-phenylisoxa2ol-4-yl)phenyl]suKonyl] propanamide, sodium salt, parecoxib sodium: A potent and selective inhibitor of COX2 for parenteral administration. Talley JJ, Bertenshaw SR, Brown DL, Carter JS, Graneto MJ, Kellogg MS, Koboldt CM, Yuan J, Seibert K, Lenz GR CHEMTRACTS 2000 13/14 917-921
52. Intensive care: Problems of over- and undersedation. Ramsay MAE BAILUERES CUN ANAESTHESIOL 200014 2 419 - 432
53. Interleukinlβ-mediated induction of COX-2 in the CNS contributes to inflammatory pain hypersensitivity. Samad TA, Moore KA, Sapirstein A, Billet S, Allchome A, Poole S, Bonventre JW, Woolf CJ NATURE200\ 410471 -475 • The central sensitization, secondary hyperalgesia and 'aches and pains' associated with a peripheral inflammatory response are shown to be mediated by a non-neuronal mechanism involving increases in CSFinterleukin-1β levels that in turn increase COX-2 mRNA in the lumbar spinal cord, resulting in increased prostanoid (PGEJ production in the CNS.
54. Global Healthcare Bulletin. Merrill Lynch ANALYST REPORT20QI May 18
55. Ketorolac In Europe. Lewis S LANCET 1994 343 784
56. Postoperative analgesic effects of celecoxib or rofecoxib after spinal fusion surgery. Reuben SS, Connelly NR ANESTH ANALG 2000 91 1221 -1225 • Evidence for the analgesic effect of prototype COX-2 inhibitors, rofecoxib and celecoxib. in the perioperative period.
57. Single dose tolerability and pharmacokinetics of parecoxib sodium, a COX-2 specific inhibitor following Intramuscular administration. Karim A, Laurent A, Kuss M, Hubbard R, Qian J AM SOC ANESTHESIOLOGISTABSTR 2000 San Francisco A-944 • Pharmacokinetics of parecoxib after intramuscular injection.
58. Single dose tolerability and pharmacokinetics of parecoxib sodium following intravenous administration. Karim A, Laurent A, Qian J, Kuss M, Hubbard R AM SOC ANESTHESIOLOGIST ABSTR 2000 San Francisco A-945 • Tolerability and pharmacokinetics of parecoxib after intravenous injection.
59. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the disposition of midazolam. Ibrahim A, Karim A, Feldman J, Kharash E AM SOC ANESTHESIOLOGIST ABSTR 2000 San Francisco A-529 • Effect of parecoxib on metabolism of midazolam.
60. Effects of parecoxib, a parenteral COX-2 specific inhibitor, on the disposition of propofol. Ibrahim A, Park S, Feldman J, Kharash E AM SOC ANESTHESIOLOGIST ABSTR 2000 San Francisco A-530 • Effect of parecoxib on metabolism of propofol.
61. Pharmacia to respond to PDA action with additional clinical data In support of parecoxib. Pharmacia Corp PRESS RELEASE 2001 July 13